Graham Cookson on JCA, EU Pharma Package, and MFN pricing reshaping biotech launch strategies
Summary
Professor Graham Cookson of the Office of Health Economics explains how simultaneous European reforms—the Joint Clinical Assessment (JCA), the EU Pharma Package, and US Most Favored Nation (MFN) pricing—are altering drug development economics. He notes that JCA focuses on clinical effectiveness rather than cost-effectiveness, while the EU Pharma Package reduces orphan drug exclusivity from 10 to 9 years. Cookson argues that US MFN policies force European launch decisions to become global strategic moves, creating a 'trilemma' between EU evidence rules and national pricing constraints. He identifies three corporate responses to these pressures: delaying launches, withholding products from specific markets, or obscuring net prices through complex contracting.
Episode sections
- 0:01 – 3:21
Introduction and Guest Background
Host Mel Whittington introduces Professor Graham Cookson, CEO of the Office of Health Economics (OHE), an independent UK charity focused on health economics and pharmaceutical innovation.
- 3:21 – 6:01
Significance of European Pharma Policy Changes
Cookson explains that three major reforms—JCA, the EU Pharma Package, and MFN—are landing simultaneously, creating tension between clear direction and uncertain timing for investor variables like evidence requirements and net price.
- 6:01 – 10:10
Joint Clinical Assessment (JCA) Mechanics and Scope
JCA is defined as a European-level health technology assessment focusing on comparative clinical effectiveness and safety, distinct from regulatory approval. It does not cover cost-effectiveness, pricing, or reimbursement.
- 10:10 – 20:02
JCA Implementation Challenges and Impact on Biotech
Cookson advises biotechs to start JCA planning during pivotal trial design due to varying comparators. Early reports show JCA is complex and slow, increasing costs and risks for small biotechs without guaranteeing faster national decisions.
- 20:02 – 27:04
The EU Pharma Package: Protection and Incentives
The EU Pharma Package modifies baseline protection to 8+1 years and reduces orphan drug baseline protection from 10 to 9 years, with a potential premium to 11 for breakthrough products, aiming to incentivize broad, fast access.
- 27:04 – 29:50
Strategic Implications for Biotech CEOs
Cookson outlines five strategic shifts: plan evidence early, use joint scientific consultations, design comparative evidence for multiple member states, focus on unmet need/orphan status, and model Europe with scenarios for launch order and net price.
- 29:50 – 30:34
Most Favored Nation (MFN) Pricing Impact
US MFN policy raises the stakes for European launch decisions because European prices feed into US exposure, transforming local pricing decisions into global strategic decisions.
- 30:34 – 33:21
MFN as a Stress Test and Corporate Responses
Cookson argues MFN is a stress test for global innovation financing. He identifies three corporate responses: delay launches, withhold products from certain markets, or hide net prices through complex contracting.
- 33:21 – 35:05
The European Trilemma and Pricing Convergence
Cookson highlights a 'trilemma' where EU member states set prices under budget constraints while the EU sets evidence and trade rules. He advocates for convergence within uniformity and rejects reference pricing.
- 35:05 – 37:19
Global Market Reordering and China's Role
Biotechs may sequence European launches later and explore overlooked markets to offset potential losses. The US trade policies are viewed as an opportunity for China to become an alternative market.
Claims worth verifying
The Office of Health Economics (OHE) is the world's oldest independent health economics research organization, founded 64 years ago.
Unidentified speaker ·
How to verify: Check OHE's official website (ohe.org) for its history and founding date.
JCA is currently active for oncology and ATMPs, will expand to orphan drugs by 2028, and to all products by 2030.
Unidentified speaker ·
How to verify: Review the official EU JCA timeline and scope documents published by the European Commission or EMA.
The first JCA report for pediatric low-grade glioma required eight PICOs across three molecular subgroups from a single-arm trial, managing only one PICO.
Unidentified speaker ·
How to verify: Access the specific JCA report for pediatric low-grade glioma published by the JCA Coordination Group.
The first four JCA assessments took between one and 16 months to complete.
Unidentified speaker ·
How to verify: Review the JCA Coordination Group's annual reports or summary of the first four assessments.
The EU Council formally adopted the EU Pharma Package on September 28, 2023.
Unidentified speaker ·
How to verify: Check the official EU Council press release or legislative records for September 2023.
The EU Pharma Package reduces baseline market protection for orphan drugs from 10 years to 9 years, with a potential premium to 11 years for breakthrough products.
Unidentified speaker ·
How to verify: Review the final text of the EU Pharma Package directive or summaries from the European Commission.
New indications for existing orphan medicines will no longer earn separate exclusivity under the new EU Pharma Package.
Unidentified speaker ·
How to verify: Analyze the specific provisions on orphan drug exclusivity in the EU Pharma Package directive.
JCA does not cover cost-effectiveness, pricing, or reimbursement, which remain national competencies.
Unidentified speaker ·
How to verify: Review the JCA Regulation (EU) 2021/2282 text, which defines the scope of JCA.
Member states are only required to give the JCA report 'due consideration,' not to rely on it.
Unidentified speaker ·
How to verify: Check the legal text of the JCA Regulation regarding the obligations of member states.
Most European prices feed into US exposure under MFN policy, making local launch decisions global.
Unidentified speaker ·
How to verify: Review US legislation or executive orders related to Most Favored Nation pricing and their stated mechanisms.
MFN is a stress test of global innovation financing rather than a coherent pricing policy.
Graham Cookson ·30:47
How to verify: Analyze academic publications by Graham Cookson on pharmacoeconomics and MFN pricing models; review policy documents from the US government regarding MFN provisions.
The current pricing model does not fit with economic models based on differential pricing.
Graham Cookson ·30:57
How to verify: Review economic literature on differential pricing in pharmaceuticals and compare it with current US and EU pricing regulations.
Companies are employing three strategies: delay, run, or hide.
Graham Cookson ·31:17
How to verify: Monitor pharmaceutical launch announcements in Europe and the US for delays, withdrawals, or complex pricing structures like outcomes-based contracts.
There is evidence that products are not coming to market in rare diseases.
Graham Cookson ·31:45
How to verify: Review FDA and EMA approval databases and press releases from biotech companies regarding rare disease drug launches in Europe.
Member states set prices under tight budgets while the EU sets evidence and trade rules.
Graham Cookson ·33:31
How to verify: Review EU directives on health technology assessment and trade agreements, and compare with national pricing agency reports from EU member states.
Reference pricing is a bad idea.
Graham Cookson ·34:31
How to verify: Review economic studies comparing reference pricing systems with differential pricing systems in European countries.
The US has gifted China an opportunity in the biotech market.
Graham Cookson ·35:50
How to verify: Analyze trade data and biotech investment flows between the US, EU, and China; review policy statements from Chinese and European policymakers.
Do your own research
- Verify the current status of the EU Pharma Package implementation timeline and specific member state adoption rates.
- Review the first JCA reports for pediatric low-grade glioma to assess the actual evidence generation burden on single-arm trials.
- Analyze recent pharmaceutical company launch delays or withdrawals in European markets as evidence of the 'run' strategy.
- Check primary sources for the definition of 'breakthrough' products under the new EU orphan drug regulations to understand exclusivity eligibility.
- Examine US trade policy documents regarding MFN pricing to understand its legal basis and potential impact on global pricing structures.
- Look for data on outcomes-based contracting prevalence in Europe to assess the 'hiding' strategy's effectiveness.
- Review OHE publications for detailed economic models of the European 'trilemma' and reference pricing impacts.
Full transcriptexpand
- 0:01
- Unidentified speaker: Welcome to Perspectives, a signature podcast series from the Learing Center for Pharmacoeconomics.
- 0:07
- Unidentified speaker: Hosted by Dr.
- 0:08
- Unidentified speaker: Mel Whittington, we will be hearing from industry leaders about the incentives for and impacts of healthcare innovation.
- 0:15
- Unidentified speaker: Welcome back to Perspectives, everyone.
- 0:17
- Unidentified speaker: I'm Mel Whittington, and this is the podcast where we try to look at healthcare innovation through a health economics lens.
- 0:25
- Unidentified speaker: And I get to talk to really great people like the guest today and hear what is happening and then try to figure out what this all means for those who are building and backing new medicines.
- 0:35
- Unidentified speaker: And so the topic today is a fun one.
- 0:38
- Unidentified speaker: We're going to get into two major changes in the European pharmacy, pharmaceutical policy landscape right now.
- 0:44
- Unidentified speaker: So we're first going to talk about JCA or joint clinical assessment and hear how this changes the way clinical evidence is assessed in Europe.
- 0:53
- Unidentified speaker: And then we're going to zoom out to the EU pharma package and hear how this changes some of the incentives of drug development.
- 1:01
- Unidentified speaker: And then we're going to close by attempting to bring in MFN, most favored nation pricing, and bring the US back into the conversation and figure out how MFN might fit into all of this.
- 1:13
- Unidentified speaker: So today's guest is Professor Graham Cookson, the CEO of the Office of Health Economics or OHE.
- 1:20
- Unidentified speaker: Graham, can you kick us off by just telling us a little bit about you and the great work of OHE?
- 1:25
- Unidentified speaker: Sure.
- 1:26
- Unidentified speaker: Well, thanks for having me, Mel.
- 1:28
- Unidentified speaker: Well, I'm an economist that focuses on health, and I like to kind of make that distinction from a health economist and don't want to offend any of those.
- 1:37
- Unidentified speaker: But in many ways, in my career, I stumbled into health economics later.
- 1:41
- Unidentified speaker: And as you said, I have the great pleasure of leading the Office of Health Economics, which is the world's oldest independent health economics research organization.
- 1:51
- Unidentified speaker: We've been going for now, what are we, 64 years?
- 1:54
- Unidentified speaker: Wow.
- 1:55
- Unidentified speaker: We're in the UK.
- 1:57
- Unidentified speaker: We're a registered charity.
- 1:59
- Unidentified speaker: So people not familiar with that, that means essentially we're a not-for-profit.
- 2:02
- Unidentified speaker: But whilst we are based in London in the UK, we we work globally across uh pretty much most countries, actually.
- 2:10
- Unidentified speaker: Uh personally, my work focusing uh focuses primarily now on the economics of pharmaceutical innovation.
- 2:17
- Unidentified speaker: And right now, the big focus is obviously the global effects of US policy decisions.
- 2:22
- Unidentified speaker: So, as we might get onto at some point, uh MFN.
- 2:26
- Unidentified speaker: And I think you know, for your listeners, what I'm working on is really where a lot of the commercial risk for biotech exists right now.
- 2:33
- Unidentified speaker: So I'm hoping they'll find today's conversation valuable.
- 2:37
- Unidentified speaker: Yeah, I without a doubt.
- 2:39
- Unidentified speaker: And I loved how you said, what was it?
- 2:41
- Unidentified speaker: You're an economist working on health.
- 2:43
- Unidentified speaker: So I've always had a little bit of an identity crisis of like, I wouldn't consider myself an economist.
- 2:48
- Unidentified speaker: I wouldn't consider myself a health economist.
- 2:50
- Unidentified speaker: I like to say I'm a pharmacoeconomist.
- 2:52
- Unidentified speaker: At least that's what I like to say right now.
- 2:54
- Unidentified speaker: That's that shifted some.
- 2:56
- Unidentified speaker: Um, and you know, I've had the pleasure of working with the OHE team on a few things, and it's, you know, a great team and excited to pick your brain on these topics today.
- 3:05
- Unidentified speaker: Again, thank you for being here.
- 3:07
- Unidentified speaker: Um, but before we get into our topics, this audience, biotech executives, investors, just more broadly, why do you think they should be paying attention to European pharmaceutical policy right now?
- 3:21
- Unidentified speaker: So let's just take a step back.
- 3:23
- Unidentified speaker: I think pharma policy in general sets three things that are kind of critically important for investors, right?
- 3:30
- Unidentified speaker: It's the evidence they're going to need, the length of protection they're going to get, and then ultimately the net price they're going to earn.
- 3:38
- Unidentified speaker: And right now in Europe, all three are moving at once.
- 3:42
- Unidentified speaker: So it's quite an unusual time and quite an uh an interesting time.
- 3:47
- Unidentified speaker: The EU is adopting some of the biggest changes to medicines, policy, and law for pretty much 20 years.
- 3:56
- Unidentified speaker: Uh, we're going to get onto it, but JCA, Joint Clinical Assessment, is now producing real reports about real products.
- 4:04
- Unidentified speaker: We all know that the US is trying to reference uh many countries' prices, including many of those in Europe.
- 4:11
- Unidentified speaker: Uh and therefore, even if your big market, your primary launch market is going to be the US, I still think that acquirers and investors will value that European tail of revenue.
- 4:23
- Unidentified speaker: And therefore, these big changes will impact valuation models.
- 4:29
- Unidentified speaker: I think we just I think we just got our soundbite for this episode.
- 4:34
- Unidentified speaker: Um, so you mentioned this a little bit, but I want to reiterate it.
- 4:39
- Unidentified speaker: How significant a period of change are we in right now?
- 4:45
- Unidentified speaker: Okay, this is where I get to be an academic, right, and sit on the fence.
- 4:47
- Unidentified speaker: So, in many respects, these are the most significant changes, isn't it?
- 4:53
- Unidentified speaker: I don't know, 2025 years, right?
- 4:55
- Unidentified speaker: So they're really big.
- 4:57
- Unidentified speaker: Uh, but at the same time, they're staged.
- 5:00
- Unidentified speaker: So we've got to be careful about how quickly they're going to impact the licenses sector, how quickly they'll bite.
- 5:07
- Unidentified speaker: So the key thing that makes this very unusual is we've got three reforms landing together and pulling in different directions, and that's the real tension.
- 5:16
- Unidentified speaker: But if we think about JCA, right now it's focused on a narrow set of products.
- 5:22
- Unidentified speaker: By 2028, that widens to orphan drugs.
- 5:24
- Unidentified speaker: By 2030, everything's in.
- 5:27
- Unidentified speaker: The pharma package that we're going to get onto, technically, it still needs a parliamentary vote.
- 5:32
- Unidentified speaker: And then, you know, those aren't familiar with with the EU kind of wranglings.
- 5:36
- Unidentified speaker: There's a period of what we call national transposition, which is when individual countries translate that into their own laws, and that could take up to two years.
- 5:45
- Unidentified speaker: And then the big thing, MFN, right?
- 5:47
- Unidentified speaker: We we know it's contested, we don't have a settled position, so the impacts are uncertain.
- 5:52
- Unidentified speaker: So I think the bottom line is that direction is clear, but the timing is going to be uncertain.
- 5:58
- Unidentified speaker: Got it.
- 5:59
- Unidentified speaker: Well, let's dig into each one of those things.
- 6:01
- Unidentified speaker: Starting with JCA, joint clinical assessment.
- 6:04
- Unidentified speaker: Yeah.
- 6:05
- Unidentified speaker: You know, for someone investing or working in biotech who they've probably heard of JCA, but they don't probably live and breathe it like you and your team does.
- 6:14
- Unidentified speaker: Can you just, you know, simply describe what it is and maybe what it what it is intended to do?
- 6:22
- Unidentified speaker: Yeah, yeah, sure.
- 6:23
- Unidentified speaker: So it starts with this fundamental question.
- 6:27
- Unidentified speaker: Is this new treatment worth paying for?
- 6:30
- Unidentified speaker: Now, before JCA, every country answers that question on their own, assessing essentially the same clinical evidence, but with different questions, different formats.
- 6:41
- Unidentified speaker: And it's pretty obvious that duplicates work for the companies.
- 6:45
- Unidentified speaker: It's efficient in terms of wasting time for those various health technology assessment bodies in each country.
- 6:51
- Unidentified speaker: And so JCA theoretically moves that clinical part to the European level.
- 6:57
- Unidentified speaker: So there is meant to be one joint report on relative clinical effectiveness and safety.
- 7:02
- Unidentified speaker: But for your kind of US listeners, just stress this is not about the regulators.
- 7:07
- Unidentified speaker: This isn't the regulator's job.
- 7:09
- Unidentified speaker: The EMA, the European Medicines Agency, like the FDA, they decide whether or not the medicine is safe and effective enough to be sold.
- 7:17
- Unidentified speaker: But JCA asks us a very slightly different question, which is how much better is it than what patients get today against the standard of care?
- 7:26
- Unidentified speaker: And yeah, broadly we call that health technology assessment.
- 7:30
- Unidentified speaker: And technically, there's there's no formal equivalent of that in the US.
- 7:34
- Unidentified speaker: The closest, even in Europe, is Germany's IGWIG, which assesses added clinical benefit.
- 7:40
- Unidentified speaker: Many people will have heard of NICE in the UK, technically in England.
- 7:44
- Unidentified speaker: Uh, that actually goes a step further because it adds cost effectiveness.
- 7:48
- Unidentified speaker: But JCA, it's only the clinical part.
- 7:51
- Unidentified speaker: It doesn't cover cost effectiveness, it doesn't cover pricing or reimbursement.
- 7:56
- Unidentified speaker: They are all national level competences.
- 8:01
- Unidentified speaker: And why did we have it?
- 8:02
- Unidentified speaker: Why is it here?
- 8:03
- Unidentified speaker: The problem it's intended to solve.
- 8:04
- Unidentified speaker: Well, honestly, it's really about duplication.
- 8:07
- Unidentified speaker: Technically, there are four stated aims: reduce duplication, strengthen cooperation, improve quality and consistency, and support timely and equitable access.
- 8:16
- Unidentified speaker: But fundamentally, it was about duplication.
- 8:19
- Unidentified speaker: Now, the interesting thing for me is what interest what industry really wanted to get out of this was that JCA would replace the national clinical step rather than adding to it.
- 8:30
- Unidentified speaker: So it would genuinely remove that duplication.
- 8:33
- Unidentified speaker: And what they wanted, therefore, is those countries to be forced to apply that report, to use that report.
- 8:39
- Unidentified speaker: But actually, when the JCA was developed, they actually lost that argument.
- 8:43
- Unidentified speaker: So right now, member states keep their flexibility.
- 8:47
- Unidentified speaker: So the final law that we are using only requires countries to give the report due consideration.
- 8:55
- Unidentified speaker: So we're kind of only halfway there.
- 8:58
- Unidentified speaker: So we've got shared clinical assessment, but without any guarantee that countries are actually going to rely on it.
- 9:04
- Unidentified speaker: Interesting.
- 9:05
- Unidentified speaker: Okay, so let me try to summarize this because that was very clear, but let me see if I can summarize it and tell me what I get wrong.
- 9:11
- Unidentified speaker: So EMA, regulatory approval, that's not what JCA is.
- 9:16
- Unidentified speaker: JCA is really focused on what it, what could the medicine be worth, comparative effectiveness, things like that.
- 9:22
- Unidentified speaker: And so health technology assessment, we don't have a centralized body in the US, but it is very common, X US, and it looks at comparative effectiveness and then can do cost effectiveness, things like that.
- 9:34
- Unidentified speaker: Is it fair to say that JCA is really focused on that clinical evidence, comparative effectiveness piece?
- 9:41
- Unidentified speaker: Um it's not necessarily cost effectiveness, what price should the drug be, that kind of thing.
- 9:48
- Unidentified speaker: Exactly, right?
- 9:48
- Unidentified speaker: So it comes after the EMA, the FDA kind of level.
- 9:53
- Unidentified speaker: It's just about clinical effectiveness, and it doesn't touch the all-important economic evidence, the pricing, reimbursement, none of that.
- 10:01
- Unidentified speaker: And the economic evidence, pricing and reimbursement, is that still at the individual country level?
- 10:07
- Unidentified speaker: Yes.
- 10:08
- Unidentified speaker: Yes, it is.
- 10:08
- Unidentified speaker: Yeah.
- 10:09
- Unidentified speaker: Okay.
- 10:10
- Unidentified speaker: One thing I try to do with guests of this podcast is to have them try to put themselves in the shoes of someone running a development stage biotech company.
- 10:19
- Unidentified speaker: And so if you were the CEO of a development stage biotech company, when should you start thinking about JCA?
- 10:28
- Unidentified speaker: Yeah, so unfortunately, because I don't think anyone really wants to hear this, it's earlier than anyone actually does.
- 10:35
- Unidentified speaker: Right.
- 10:35
- Unidentified speaker: So there's one thing to take away.
- 10:37
- Unidentified speaker: It's get ahead of it.
- 10:39
- Unidentified speaker: Because really, you should be doing this when you're designing the pivotal program, because by the time the JCA scope is set, your trial is already fixed.
- 10:49
- Unidentified speaker: So you've got to get in there early.
- 10:51
- Unidentified speaker: And essentially, if you're in oncology or ATMPs, JCA is active now for you.
- 10:57
- Unidentified speaker: By 2028, orphan medicines will be kind of in scope by 2030, basically everything.
- 11:03
- Unidentified speaker: So a company already starting a phase two program today should assume it's it's going to be in JCA no matter what it is.
- 11:10
- Unidentified speaker: So uh I think earlier, uh, the practical route in it is a joint scientific consultation, which is a voluntary dialogue that can run alongside the EMA, so the European Medicines Agency scientific advice.
- 11:22
- Unidentified speaker: So you can do it in parallel.
- 11:24
- Unidentified speaker: Uh and we're already seeing in some countries them turning off their kind of national scientific advice.
- 11:29
- Unidentified speaker: So France no longer does that, uh, focusing on the joint route.
- 11:33
- Unidentified speaker: And I think other countries are going to follow suit over the next couple of years as well.
- 11:37
- Unidentified speaker: So start early.
- 11:39
- Unidentified speaker: Start early.
- 11:40
- Unidentified speaker: You know, it goes to all drugs in 2030.
- 11:44
- Unidentified speaker: So if you have pipeline products, it's good to be thinking about it right now, um, before the pivotal program, especially.
- 11:51
- Unidentified speaker: How should they be thinking about it?
- 11:53
- Unidentified speaker: I mean, I hear you that it should largely be on the clinical development side.
- 11:56
- Unidentified speaker: Is this comparator selection, endpoints, subgroup analyses, overall trial design, or are there any specific tips for how they should be thinking about it in addition to when?
- 12:07
- Unidentified speaker: Yeah, so I mean, I think the direct answer is that you're designing for many different standards of care, not one.
- 12:15
- Unidentified speaker: And this is the real challenge, and this is what's kind of the evidence of the early, um, early reports are showing.
- 12:20
- Unidentified speaker: So member states set the comparators.
- 12:23
- Unidentified speaker: Uh, and because kind of standard of care treatment differs from country to country, you can face several comparators, which is a real problem.
- 12:31
- Unidentified speaker: So you can either run your trial against the comparator that matters most or plan credible indirect comparisons for the for the rest.
- 12:39
- Unidentified speaker: Endpoints need to be the ones assessors see as patient relevant, so survival, quality of life.
- 12:46
- Unidentified speaker: And surrogates are going to need justify.
- 12:48
- Unidentified speaker: Subgroups are going to have to be predefined, not found after the fact.
- 12:52
- Unidentified speaker: And the trial population has to look like European patients on European care.
- 12:58
- Unidentified speaker: So it kind of largely makes sense to be recruiting from Europe.
- 13:03
- Unidentified speaker: And really, as I said, that's really about the standards of care, the different treatment options, than it is about things such as ethnic diversity.
- 13:10
- Unidentified speaker: Uh, and I mean, if if we think about the first JCA, so that was published in in June for uh Ibsen's products uh for brain tumour in low-grade uh glioma in children.
- 13:24
- Unidentified speaker: Um, I mean that was a I mean it's an interesting one to start with.
- 13:28
- Unidentified speaker: It's a really hard case because you you've got a rare disease single arm trial with biomarker-defined subgroups, and it just shows all of the challenges because for that one tumor, member states asked for eight PICOs, right?
- 13:42
- Unidentified speaker: I'm sure your audience know that's population intervention compared to an outcome, right?
- 13:46
- Unidentified speaker: So eight PICOs across three molecular subgroups and a single arm pivotal trial managed to get one of them.
- 13:54
- Unidentified speaker: So then the evidence narrowed again with fewer 20% of those enrolled patients in the relevant arms were considered representative of the pay of that patient population.
- 14:04
- Unidentified speaker: Remember, it's about standards of care.
- 14:07
- Unidentified speaker: So it's becomes a fraction of a fraction.
- 14:10
- Unidentified speaker: So, you know, what OHE would say, we've done some work on this, which I'm by the way, for your listeners, everything that we do is is freely available on our website.
- 14:19
- Unidentified speaker: So you you can pop along ohe.org and find all our reports.
- 14:22
- Unidentified speaker: Uh, and I'm sure everyone is already subscribed to our mailing list, so they're getting if not, they should be.
- 14:27
- Unidentified speaker: I am so much.
- 14:29
- Unidentified speaker: Um, but you know, one of the arguments we make is precision requires precisions on both sides of the comparison.
- 14:35
- Unidentified speaker: And we've got to get better evidence generation, not lower standards.
- 14:39
- Unidentified speaker: So we need to think about different trial designs, basket umbrella adaptive designs, et cetera.
- 14:45
- Unidentified speaker: But also, honestly, structured real-world evidence is is gonna be a key to to trying to fix this, but it's pretty hard.
- 14:53
- Unidentified speaker: Yeah, and and when we were first talking about JCA and we talked about this duplication piece.
- 14:58
- Unidentified speaker: And so in my head, I'm like, oh, does this make European market access simpler?
- 15:02
- Unidentified speaker: You know, like are we reducing some duplication, streamlining things?
- 15:05
- Unidentified speaker: And then we talked about variable standard of care.
- 15:08
- Unidentified speaker: And um, so does this make European market access simpler?
- 15:14
- Unidentified speaker: I mean, uh, probably no, not not yet.
- 15:18
- Unidentified speaker: I mean, you've got to probably be cautious about promising it ever will.
- 15:22
- Unidentified speaker: I mean, it it simplifies the architecture or the the process because well, there's one clinical dossier, right?
- 15:29
- Unidentified speaker: I mean, that's one left.
- 15:31
- Unidentified speaker: Uh, but it actually doesn't simplify any of the science, and it's we started to get into right, it's actually really hard because you're trying to do all of that, but just put it into one place.
- 15:39
- Unidentified speaker: So the first report was over 150 pages for a single Pico that it managed to do, right?
- 15:46
- Unidentified speaker: They wanted seven others.
- 15:48
- Unidentified speaker: Uh, the full manufacturer's submission was longer.
- 15:51
- Unidentified speaker: And even when you do that, you've still got the national processes afterwards, because remember what I said that they they have to give it due consideration, but they they don't actually have to rely on that report.
- 16:02
- Unidentified speaker: So it's not replacing that national piece that's adding in.
- 16:05
- Unidentified speaker: Yeah, right.
- 16:06
- Unidentified speaker: So, I mean, okay, so let's give them the benefit of the doubt, it's early days, and and we know that this is a very risk-averse sector.
- 16:14
- Unidentified speaker: But even the own agency's verdict on the first four reports is that whilst the system is feasible and the quality is defensible, yes, the foundations are there, but it, you know, we're still a long way from seeing this as a simpler, uh, faster process, really.
- 16:31
- Unidentified speaker: Uh, and I mean, like the first four assessments each took between a year and 16 months.
- 16:37
- Unidentified speaker: I mean, you know, that's not a definition of speed, right?
- 16:40
- Unidentified speaker: So um and uh there was a meeting recently of some of the the chiefs of agencies, and and you know, they really raised also just the capacity question.
- 16:50
- Unidentified speaker: So, you know, Spain said they would want to do more of these JCAs, they'd like to assess more of them, but it it it takes too long and they don't have the capacity to to do it.
- 16:59
- Unidentified speaker: So, really a process that's meant to lighten the load is actually heavy for regulators, and it's it's actually quite risky for companies because you're gonna try and do this once.
- 17:09
- Unidentified speaker: Yeah.
- 17:10
- Unidentified speaker: Well, I liked what you said about a simpler architecture, but that's not necessarily translate into a simpler or a faster process, which I think is really well said.
- 17:19
- Unidentified speaker: Um, shoot, I have so many questions about this, but we do have other topics we want to get into too.
- 17:24
- Unidentified speaker: But maybe wrapping up on the JCA conversation, how does this change like the economics of drug development?
- 17:33
- Unidentified speaker: If we bring this back to drug development and investors and biotech CEOs, does this I'm gonna call it an additional process of European market access?
- 17:45
- Unidentified speaker: Does this change the economics of developing a drug for Europe?
- 17:49
- Unidentified speaker: I mean, I I think it does, but probably not in a really positive way right now.
- 17:54
- Unidentified speaker: So certainly it changes costs and risks more than it does revenue.
- 17:58
- Unidentified speaker: So, you know, for biotechs and they're small and they might be tight in funding, those costs may go up, but they're also gonna hit a lot earlier because you need to start doing this comparative evidence earlier.
- 18:09
- Unidentified speaker: And obviously that you know impacts on the investment side and how much cash they're gonna need.
- 18:14
- Unidentified speaker: But also the risk goes up because your gap in your comparative evidence is not just in one document that you can kind of move on and do another country and move to another member state, right?
- 18:24
- Unidentified speaker: You can't learn by doing anymore.
- 18:26
- Unidentified speaker: You you know, if it's in that document, everyone's got it.
- 18:30
- Unidentified speaker: So that's a big problem.
- 18:32
- Unidentified speaker: But you know, there is an upside, so you stop writing the same clinical dossier many times, I guess.
- 18:37
- Unidentified speaker: That's the duplication point.
- 18:38
- Unidentified speaker: But essentially, JCA is not interested in in reimbursed prices, so it doesn't even guarantee reimbursement.
- 18:45
- Unidentified speaker: So the kind of net effect on a product is essentially going to be modest next to the big things you care about, like price and exclusivity.
- 18:53
- Unidentified speaker: So, you know, I I think it it's it's not.
- 18:56
- Unidentified speaker: I mean, really, again, Owen China kind of latest report said this, but we argue that uncertainty about the reimbursable population could weaken incentives to launch and invest in precision medicines in Europe.
- 19:09
- Unidentified speaker: But and it's a really big but if the JCA speeds up those national decisions, then that time to earlier access could outweigh the extra evidence cost.
- 19:18
- Unidentified speaker: But I mean, my big caveat is they're like butting massive letters.
- 19:22
- Unidentified speaker: Uh and we haven't seen that yet.
- 19:24
- Unidentified speaker: We haven't got any evidence there, right?
- 19:26
- Unidentified speaker: Yeah, at the minute.
- 19:27
- Unidentified speaker: So it's kind of theoretically this could help.
- 19:31
- Unidentified speaker: But I think right now, in the stage we're at, where we're still learning how it's gonna work, I wouldn't say it it's net positive for small biotechs.
- 19:40
- Unidentified speaker: Got it.
- 19:41
- Unidentified speaker: Okay.
- 19:42
- Unidentified speaker: Um, so we're gonna switch to the EU pharma package, but maybe if you guys would be willing to share some of your published resources on JCA, I can link them in the show notes because I feel like we just put out so many great teasers and I know I want to dig in more, and I'm sure the listeners will too.
- 19:57
- Unidentified speaker: So hopefully we can link those.
- 19:59
- Unidentified speaker: Um, EU pharma package.
- 20:02
- Unidentified speaker: What is it?
- 20:03
- Unidentified speaker: Um and in my limited research of it, it seemed like there was a lot in there.
- 20:09
- Unidentified speaker: So if you could just identify maybe two or three things that biotech execs and investors should really understand about this package.
- 20:19
- Unidentified speaker: Yeah, okay.
- 20:20
- Unidentified speaker: So I'm gonna take the biggest number you gave me there.
- 20:22
- Unidentified speaker: So let's focus on three things I think massively is.
- 20:26
- Unidentified speaker: So again, from a European perspective, this is probably the biggest thing in in about 20, 25 years.
- 20:33
- Unidentified speaker: And we see three big changes.
- 20:34
- Unidentified speaker: The first is going to be to baseline protection structure.
- 20:37
- Unidentified speaker: So we're getting eight years of data protection plus one year of market protection with some extensions for various criteria, but they're not given.
- 20:47
- Unidentified speaker: Second, around orphan drugs, so rare diseases, there's going to be a lower baseline protection, which is not good news, but then with a premium for breakthrough products, we can get into whether or not that's realistic in rare diseases.
- 21:00
- Unidentified speaker: Uh and third, uh, new transferable exclusivity voucher for priority antimicrobials.
- 21:07
- Unidentified speaker: So I mean uh the good news is that the original proposals were significantly harsher and they have definitely been softened.
- 21:18
- Unidentified speaker: Okay.
- 21:18
- Unidentified speaker: Um but but these are not uh these are you know not net positive positive generally for industry.
- 21:25
- Unidentified speaker: And I think there's also a really big major tension with MFN that we might get onto.
- 21:30
- Unidentified speaker: But I mean, basically, the big goal of the EU pharma package from the legislator's perspective is to encourage broader access across European countries, right?
- 21:39
- Unidentified speaker: So it's going to combine incentives with punishments.
- 21:42
- Unidentified speaker: Oh no.
- 21:43
- Unidentified speaker: So we've got carrots and sticks going everywhere.
- 21:46
- Unidentified speaker: Um, but the big problem is that the obvious response to MFN for a lot of companies is to wait and see.
- 21:52
- Unidentified speaker: So that may be delaying launches or slowing launches, and that fundamental strategy runs against the whole point of the EU pharma package.
- 22:01
- Unidentified speaker: Ah, because the EU pharma package is more not wait and see, quicker pace, quicker pace, but then MFN.
- 22:09
- Unidentified speaker: Okay, so let's try to get into that because we will absolutely get into MFN.
- 22:13
- Unidentified speaker: But a question on the EU pharma package, and you talked about this in your opening remarks about um, you know, I think it was like European Parliament.
- 22:24
- Unidentified speaker: Where does the EU pharma package stand today?
- 22:27
- Unidentified speaker: Like, is this a done deal?
- 22:29
- Unidentified speaker: Is this for sure happening?
- 22:30
- Unidentified speaker: Are there still things that have to be decided, or or when should we be expecting this to happen?
- 22:36
- Unidentified speaker: Yeah, okay.
- 22:36
- Unidentified speaker: So, I mean, European politics is pretty crazy, even for someone that lives in Europe.
- 22:41
- Unidentified speaker: But um, the council formally adopted it in September this year, 28th of September.
- 22:47
- Unidentified speaker: So that was following the political agreement on the substance last December.
- 22:51
- Unidentified speaker: So uh the kind of the substance, the content is fixed.
- 22:56
- Unidentified speaker: Now we're into the kind of implementation stage.
- 22:58
- Unidentified speaker: And so, as I said, it still needs a vote in the European Parliament, which I think someone might correct me, I think is November.
- 23:05
- Unidentified speaker: That then if technically gets published in what's called the official journal, and that's the signal to those individual member states to transpose that directive into their own national laws, uh, and that can take different amounts of time, depends on how technically difficult it is in the country and how much they want to.
- 23:25
- Unidentified speaker: But basically, it takes about two years.
- 23:27
- Unidentified speaker: So I think the kind of key thing is yeah, the content, the law, the substance is settled, but when it actually impacts will vary based on when it's adopted by countries.
- 23:38
- Unidentified speaker: Okay, that's really helpful.
- 23:39
- Unidentified speaker: So it's it's happening, how and when, maybe still to be determined.
- 23:45
- Unidentified speaker: Yeah.
- 23:46
- Unidentified speaker: Um, the word you said when first talking about the EU pharma package was incentives.
- 23:51
- Unidentified speaker: It impacts the incentives and incentives around things like unmet need and orphan drugs are like right uh in in the lane of this podcast.
- 24:00
- Unidentified speaker: And so can you spend a little bit more time on those and how these incentives are structured in this package and what that might mean for development decisions?
- 24:11
- Unidentified speaker: I'm particularly like stuck on the comment you made about the rare disease orphan drugs piece.
- 24:17
- Unidentified speaker: Yeah, so I think two things are changing.
- 24:20
- Unidentified speaker: So kind of the floor falls, and then the extras or the add-on protection you can get are going to matter more.
- 24:27
- Unidentified speaker: So baseline market protection drops from two years to one, but the overall ceiling is pretty much where it is today at 11, depending upon whether or not you earn any of the extensions.
- 24:39
- Unidentified speaker: So if you don't, you've probably lost about a year.
- 24:42
- Unidentified speaker: So it it's it's kind of not that massive, but I know everything matters, but in the grand scheme of things.
- 24:49
- Unidentified speaker: Uh so what really happens is it's more a shift from guaranteed protection towards earn protection.
- 24:55
- Unidentified speaker: So as I said, it's trying to incentivize and reward particular types of assets.
- 24:59
- Unidentified speaker: So uh I mean, you know, from an investor perspective, arguably for most assets, patents and SPCs are the binding constraint anyway.
- 25:09
- Unidentified speaker: So it's going to make a modest effect uh on average uh kind of products, but it'll have a wider spread, I think, between kind of the winners and losers.
- 25:20
- Unidentified speaker: Got it.
- 25:20
- Unidentified speaker: So the incentives are um a little differentiated based on um, you know, breakthroughs or or unmet medical need.
- 25:31
- Unidentified speaker: Yeah, so I mean, for orphan products, the baseline falls from 10 to 9 years, and then there's a premium back up to 11 years for what they call breakthrough products.
- 25:40
- Unidentified speaker: That's pretty narrowly defined.
- 25:42
- Unidentified speaker: So it's no product is already authorized for the condition, and the medicine delivers a clinically relevant reduction in morbidity or mortality.
- 25:50
- Unidentified speaker: So um that can be quite challenging for um um for for orphan drugs uh because new indications for existing orphan medicines will no longer earn separate exclusivity, and you know, most a lot of orphan drugs are you know first developed in in for one indication and then um and then applied to different areas.
- 26:12
- Unidentified speaker: So it really tilts that incentive towards first in condition medicines and away from sequential indication strategies.
- 26:19
- Unidentified speaker: And I think the problem is that's not really what happens in in rare diseases and orphan medicines.
- 26:24
- Unidentified speaker: Um, it's not even kind of how the science kind of works with it at the moment.
- 26:27
- Unidentified speaker: So I I kind of I know what we're trying to do here.
- 26:32
- Unidentified speaker: It's really trying to incentivize and reward that kind of breakthrough innovation.
- 26:36
- Unidentified speaker: But I just I I wonder can it have an impact when most of the world is set up to understand what the US values?
- 26:44
- Unidentified speaker: Right.
- 26:45
- Unidentified speaker: I mean, Europe's important, but it's it's really secondary to what what's happening in the US.
- 26:49
- Unidentified speaker: Which is why we can't have this conversation without breaking up MFN.
- 26:54
- Unidentified speaker: Um, but I have two more questions that I want to ask before we get to MFN.
- 26:58
- Unidentified speaker: I again want to kind of make you put yourself in the shoes of a biotech CEO.
- 27:04
- Unidentified speaker: What should you be doing differently, considering the EU pharma package?
- 27:08
- Unidentified speaker: The content is going to hold, implementation and timing still to be to be determined.
- 27:14
- Unidentified speaker: But is there anything that they can do differently to prepare themselves better?
- 27:21
- Unidentified speaker: So yeah, I'm gonna talk more broad think more broadly about how how these kind of interact because I think it's it's helpful.
- 27:28
- Unidentified speaker: So I think there's five things to think about.
- 27:32
- Unidentified speaker: So, first, as I said, um you've got to plan that evidence generation for the regulator and for JCA from the start.
- 27:41
- Unidentified speaker: And I think I said already, I think using the joint scientific consultation if you're in scope is important.
- 27:47
- Unidentified speaker: And then back to what we said before, design that comparative evidence and for recruitment in more than one member state because that actually counts now towards extra protection.
- 27:57
- Unidentified speaker: Um focus on that unmet need and that orphan status is something to plan for, uh not to assume.
- 28:04
- Unidentified speaker: So, is it going to apply?
- 28:06
- Unidentified speaker: Will that help you?
- 28:07
- Unidentified speaker: Uh, and I think you're gonna have to model Europe in scenarios for different launch order and net price.
- 28:13
- Unidentified speaker: So I wouldn't be building the European case on a single list price because of MFN.
- 28:18
- Unidentified speaker: Um, I think bottom line though, it's just making it really hard.
- 28:23
- Unidentified speaker: So the interaction of JCA, European Pharma Package, and MFN means that the right answer is really asset specific.
- 28:32
- Unidentified speaker: Um, and it's it's it's it's it's a big burden.
- 28:35
- Unidentified speaker: There's a lot to think about.
- 28:37
- Unidentified speaker: So even though it's asset specific, which I complet I completely understand that, is it fair to say that the European development or launch strategy is different than it was before JCA and EU pharma package and MFN?
- 28:53
- Unidentified speaker: Yeah, because I again they're kind of pulling in opposite directions.
- 28:56
- Unidentified speaker: So as I said, for the for the with because of the JCA, you you've got to think really early about evidence generation and be planning to do effectively at scale at the start, so not incrementally market by market.
- 29:08
- Unidentified speaker: You know, you're not just thinking, oh, let's just think about Germany now, we'll do everything else later.
- 29:12
- Unidentified speaker: And similarly, because of the EU pharma package, what they really want is fast and broad access across Europe.
- 29:18
- Unidentified speaker: So they're expecting and incentivizing and almost demanding that as well.
- 29:23
- Unidentified speaker: So again, uh a piecemeal market by market strategy isn't going to work.
- 29:29
- Unidentified speaker: And if you want to extract the maximum protection under the EU pharma package, you've really got to be thinking about how you're going to can you demonstrate you know that unmet need and that to get the orphan status?
- 29:43
- Unidentified speaker: I think that's so it's really start early and think broad.
- 29:49
- Unidentified speaker: Okay.
- 29:50
- Unidentified speaker: Let's bring in MFN into this.
- 29:53
- Unidentified speaker: Um how does the US interest in MFN, mostly for nation pricing, change everything we've just discussed?
- 30:05
- Unidentified speaker: Yeah, so I mean it really raises the stake for each and every European launch decision because most European prices feed into US exposure.
- 30:20
- Unidentified speaker: And even the ones that aren't in the basket may well be referenced by uh another country in the basket.
- 30:28
- Unidentified speaker: So I think that's that it makes that local decision actually a global decision.
- 30:34
- Unidentified speaker: And given how important the US market is for many companies, they're going to actually have to really think about that.
- 30:41
- Unidentified speaker: But I mean, generally, my my view is that I don't really see MFN as a pricing policy.
- 30:47
- Unidentified speaker: I think it's really a stress test of global innovation financing and how we deliver kind of fair shares rather than being some sort of coherent pricing policy.
- 30:57
- Unidentified speaker: So it, you know, putting my economics hat on, it the pricing model doesn't really fit with the economics that we use to justify it, which should be based on differential pricing.
- 31:08
- Unidentified speaker: But uh the bottom line is companies essentially have three responses, which I've talked about before, which I call delay, run, or hide.
- 31:17
- Unidentified speaker: Um, so the delay is what most companies are doing, even if they don't admit it, which is to delay.
- 31:23
- Unidentified speaker: So there's big option value now in waiting to see what happens.
- 31:28
- Unidentified speaker: The US is still the big predominant market, and Europe is still the tail.
- 31:33
- Unidentified speaker: So let's see how the policy plays out, let's see what the member countries, member states do about it.
- 31:39
- Unidentified speaker: Second is what I call run, which is a more extreme version of that, which is don't launch uh in in many European markets.
- 31:45
- Unidentified speaker: And there's some evidence that that in rare diseases that, for example, that we are seeing products not come to market.
- 31:52
- Unidentified speaker: And then the third strategy is what I call hide.
- 31:55
- Unidentified speaker: And that's it, we're not clear that that's going to be an effective strategy, but by that I mean hide the price.
- 32:01
- Unidentified speaker: So, what tools can be used to effectively try and disguise the net price?
- 32:05
- Unidentified speaker: Is that greater use of outcomes-based contracting, bundling of products and services?
- 32:11
- Unidentified speaker: Uh, what would obfuscate a clear net price?
- 32:15
- Unidentified speaker: Now, again, whether that's ultimately effective is uncertain, but they're the kind of the three strategies.
- 32:23
- Unidentified speaker: I would say, I like that summary.
- 32:26
- Unidentified speaker: I would say delay, run, and hide sharply contrasts fast and broad.
- 32:32
- Unidentified speaker: Exactly.
- 32:34
- Unidentified speaker: They're pulling in totally the opposite directions.
- 32:37
- Unidentified speaker: Yeah, so that EU pharma package intended to be fast and broad, MFN, if a strategy is delay, run, or hide, this is this is attention.
- 32:48
- Unidentified speaker: Yeah.
- 32:49
- Unidentified speaker: Okay, so if you put say there is a world with JCA, the three things we talked about, JCA, EU pharma package, and MFN together.
- 33:01
- Unidentified speaker: Like, what should biotech execs and investors should be what should they be paying attention to?
- 33:08
- Unidentified speaker: What should they be doing?
- 33:09
- Unidentified speaker: Is it, hey, they need to subscribe to the OHE lister so they can stay up to date on what this all means, or like what to do?
- 33:16
- Unidentified speaker: Yeah, come and talk to us and we'll give you an academic answer.
- 33:21
- Unidentified speaker: Uh Abid, the thing that I think we should all be paying attention to is this gap between who sets European prices and who carries the kind of consequences.
- 33:31
- Unidentified speaker: So um, member states set prices still under tight budgets, and they're all claiming affordability crises of various different scales, right?
- 33:44
- Unidentified speaker: The EU sets the evidence, the EU sets the protection rules.
- 33:48
- Unidentified speaker: The EU is the body which negotiates trade deals, and trade is being used as a lever to get higher prices.
- 33:57
- Unidentified speaker: And then we've got over in Washington this big impact on allegedly on net prices through their kind of trade policies.
- 34:07
- Unidentified speaker: And at the heart of all of this, many European countries are big life sciences hubs and want to protect that.
- 34:14
- Unidentified speaker: I think they've kind of got an industrial uh policy sector.
- 34:18
- Unidentified speaker: So there's this really kind of this trilemma.
- 34:21
- Unidentified speaker: So, what I think we need to see, and the most constructive solution, is some level of convergence, but within uniformity.
- 34:31
- Unidentified speaker: So, without uniformity, sorry, I think you know, reference pricing is a really bad idea.
- 34:36
- Unidentified speaker: We shouldn't all be paying the same price.
- 34:38
- Unidentified speaker: There's there's there's no reason for that.
- 34:40
- Unidentified speaker: But I think a lot of European countries do have to accept that they haven't been paying the fair share of the innovation costs of medicines.
- 34:50
- Unidentified speaker: I'd like to see more thought about broader value in in value-based assessments across Europe that would help bring up prices, but always recognize some of the social values of medicines.
- 35:05
- Unidentified speaker: Um, now, if we don't see Europe moving on some of this, I'd say for biotechs, I'd be planning for Europe to be sequenced much later.
- 35:15
- Unidentified speaker: I know that even some of the large pharmaceutical companies are thinking about that.
- 35:20
- Unidentified speaker: They're also asking whether markets that have perhaps been overlooked historically, those that will be outside the basket, um, could make up for the losses that they may see by not launching in in Europe as early.
- 35:34
- Unidentified speaker: So we might even see a kind of a reordering globally of that.
- 35:40
- Unidentified speaker: And then the last thing, you probably asked for one, I can't remember, but I'm gonna give you a question.
- 35:44
- Unidentified speaker: No, that's great.
- 35:45
- Unidentified speaker: Keep going.
- 35:46
- Unidentified speaker: What's happening with China, right?
- 35:48
- Unidentified speaker: So um we've got China.
- 35:50
- Unidentified speaker: Um, I think they the US has gifted China this this opportunity.
- 35:57
- Unidentified speaker: I think there are a lot of people, a lot of policymakers in Europe saying, well, if the risk, if the threat from the US is that if we don't pay higher prices, we don't get new drugs, then what about China?
- 36:09
- Unidentified speaker: Will they be riding in on a horse offering us gifts?
- 36:13
- Unidentified speaker: Um, and and also it's a really big market for for biotech.
- 36:19
- Unidentified speaker: So again, if Europe is problematic, is launching into China an opportunity as well.
- 36:24
- Unidentified speaker: So um, yeah, lots to think about.
- 36:29
- Unidentified speaker: It's not gonna be a quiet period for anybody.
- 36:33
- Unidentified speaker: Lots to think about.
- 36:34
- Unidentified speaker: I I love how that just closed this episode.
- 36:38
- Unidentified speaker: Um, I've learned so much.
- 36:40
- Unidentified speaker: This was great.
- 36:41
- Unidentified speaker: Your perspective was brilliant, and I appreciate you sharing it with us.
- 36:44
- Unidentified speaker: Please do send me some of the resources OHE has put in so I can put it in the show notes, and all these people can access it.
- 36:50
- Unidentified speaker: But thank you so much.
- 36:52
- Unidentified speaker: You're welcome, Mel.
- 36:54
- Unidentified speaker: Thanks for having me on.
- 36:55
- Unidentified speaker: I'll talk to you soon.
- 36:56
- Unidentified speaker: Bye.
- 37:06
- Unidentified speaker: Thank you for listening to this episode of Perspectives.
- 37:08
- Unidentified speaker: If you're interested in participating in future podcasts or would like to learn more about the Learing Center for Pharmacoeconomics, please email cpe at metacorp.com.